Veru Inc. Common Stock (VERU)

FairStock Score: 68/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses with durable earnings and a margin of safety. Veru does not fit that mold today. It is a late clinical-stage biopharmaceutical company with about 20 employees, developing medicines for metabolic disease, oncology and viral-induced ARDS, plus the FC2 female condom. The filed numbers show persistent losses: in fiscal 2025, net income was -$22.7M and diluted EPS -$1.55; in fiscal 2024, revenue was $16.9M but net income was -$37.8M and diluted EPS -$2.80; fiscal 2023 had revenue of $16.3M and a net loss of $93.2M. More recently, fiscal Q3 2026, the quarter ended 2026-06-30, showed net income of -$7.0M and diluted EPS -$0.30. Free cash flow over the trailing twelve months was -$26.0M, and FairStock's FCF yield is -69.7%. At the 2026-10-13 close of $2.19, FairStock calculated P/E -3.59, P/B 1.32, ROE -64.54%, ROCE -54.03%, Piotroski 0/9, and Altman Z -9.29. The low D/E of 0.09 is a modest positive, and losses have narrowed from fiscal 2023 to fiscal 2025. But a moat is hard to identify when revenue is not reported in the most recent filings and profits are absent. The Lynch category is none because the company lost money in each of the last four years. This is a speculative pipeline story, not a Graham-style bargain based on demonstrated earning power.

In plain English: Veru is a small drug company working on medicines for metabolic diseases, cancer, and serious breathing problems; it also sells a female condom. The business is losing money and using cash, with losses in each of the last four years. At the 2026-10-13 close of $2.19, the price looks more like a bet on future drug results than a cheap stock based on today's sales and profits.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q3 2026 10-Q (period ended 2026-06-30) · fiscal Q2 2026 10-Q (period ended 2026-03-31) · fiscal Q1 2026 10-Q (period ended 2025-12-31) · fiscal Q3 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-09-30) · FY2024 10-K (period ended 2024-09-30) · FY2023 10-K (period ended 2023-09-30)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer